Persberichten

2006

13/12/2006
ABLYNX IDENTIFICEERT NIEUWE NANOBODIES® EERSTE MIJLPAAL IN DE SAMENWERKINGSOVEREENKOMST MET PROCTER & GAMBLE


06/11/2006
ABLYNX EN WYETH SLUITEN ONDERZOEKS EN LICENTIEOVEREENKOMST AF.


16/10/2006
ABLYNX BREIDT UIT EN VERHUIST NAAR NIEUWE VESTIGING


23/08/2006
ABLYNX VOLTOOIT ZIJN EURO 40 MILJOEN (~50 MILJOEN) SERIE C FINANCIERINGSRONDE - ééN VAN DE TWEE GROOTSTE PRIVATE INVESTERINGEN IN DE EUROPESE BIOTCH VAN DIT JAAR.


01/06/2006
ABLYNX STRENGTHENS MANAGEMENT TEAM - EVA-LOTTA ALLAN JOINS AS CHIEF BUSINESS OFFICER.


18/05/2006
ABLYNX APPOINTS WIM OTTEVAERE AS CFO.


10/04/2006
ABLYNX AND PROCTER & GAMBLE EXTEND NANOBODY™ DRUG DISCOVERY AND DEVELOPMENT AGREEMENT TO METABOLIC TARGETS.


27/03/2006
ABLYNX APPOINTS EDWIN MOSES AS CEO.


14/03/2006
ABLYNX REVEALS POWER OF NANOCLONE™ -  A HIGH THROUGHPUT METHOD FOR ISOLATING HIGH POTENT ANTIBODY-DERIVED THERAPEUTIC PROTEINS (NANOBODIES™).


09/02/2006
ABLYNX ANNOUNCES RESEARCH COLLABORATION WITH KIRIN BREWERY.


18/01/2006
ABLYNX ANNOUNCES PHARMA ALLIANCE TO DEVELOP THERAPEUTIC NANOBODIES™.


11/01/2006
ABLYNX ANNOUNCES COLLABORATION WITH CENTOCOR RESEARCH AND DEVELOPMENT, INC.